Clark JW - Search Results

1

Quality of informed consent in cancer clinical trials: a cross-sectional survey.

Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Joffe S, et al. Among authors: clark jw. Lancet. 2001 Nov 24;358(9295):1772-7. doi: 10.1016/S0140-6736(01)06805-2. Lancet. 2001. PMID: 11734235

2

Biological response modifiers.

Clark JW. Clark JW. Cancer Chemother Biol Response Modif. 1996;16:239-73. Cancer Chemother Biol Response Modif. 1996. PMID: 8639384 Review. No abstract available.

3

Current perspectives on locally advanced pancreatic cancer.

Czito BG, Willett CG, Clark JW, Fernandez Del Castillo C. Czito BG, et al. Among authors: clark jw. Oncology (Williston Park). 2000 Nov;14(11):1535-45; discussion 1546, 1549-52. Oncology (Williston Park). 2000. PMID: 11125940 Review.

4

Quality of informed consent: a new measure of understanding among research subjects.

Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Joffe S, et al. Among authors: clark jw. J Natl Cancer Inst. 2001 Jan 17;93(2):139-47. doi: 10.1093/jnci/93.2.139. J Natl Cancer Inst. 2001. PMID: 11208884

5

Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.

Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Bunnell CA, et al. Among authors: clark jw. Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55. doi: 10.1007/s002800100319. Cancer Chemother Pharmacol. 2001. PMID: 11761451 Clinical Trial.

6

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.

Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW. Ryan DP, et al. Among authors: clark jw. Cancer. 2000 Jan 1;88(1):180-5. doi: 10.1002/(sici)1097-0142(20000101)88:1<180::aid-cncr25>3.3.co;2-h. Cancer. 2000. PMID: 10618622 Clinical Trial.

7

Biological response modifiers.

Clark JW. Clark JW. Cancer Chemother Biol Response Modif. 1999;18:223-38. Cancer Chemother Biol Response Modif. 1999. PMID: 10800485 Review. No abstract available.

8

Chemotherapy for soft tissue sarcomas.

Clark JW. Clark JW. Med Health R I. 1997 Jan;80(1):37-8. Med Health R I. 1997. PMID: 9009582 Review. No abstract available.

9

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX. Hezel AF, et al. Among authors: clark jw. Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24. Br J Cancer. 2014. PMID: 24960403 Free PMC article. Clinical Trial.

10

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.

Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. Penson RT, et al. Among authors: clark jw. Br J Cancer. 2005 Jul 11;93(1):54-9. doi: 10.1038/sj.bjc.6602671. Br J Cancer. 2005. PMID: 15986034 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results